Jane Street
AKBA icon

Jane Street’s Akebia Therapeutics AKBA Stock Holding History

Jane Street’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,300
Closed -$29.4K – 9522
2025
Q1 		$29.4K Buy
+15,300
New +$31.2K ﹤0.01% 9098
2024
Q2 		– Sell
-24,000
Closed -$43.9K – 9262
2024
Q1 		$43.9K Buy
+24,000
New +$38.4K ﹤0.01% 8768
2022
Q2 		– Sell
-157,700
Closed -$113K – 9554
2022
Q1 		$113K Buy
157,700
+128,800
+446% +$276K ﹤0.01% 9394
2021
Q4 		$65K Sell
28,900
-8,400
-23% -$22.9K ﹤0.01% 9427
2021
Q3 		$107K Buy
37,300
+300
+0.8% +$857 ﹤0.01% 9260
2021
Q2 		$140K Buy
37,000
+22,300
+152% +$75.1K ﹤0.01% 9089
2021
Q1 		$50K Sell
14,700
-9,400
-39% -$33.9K ﹤0.01% 8838
2020
Q4 		$67K Buy
+24,100
New +$70.4K ﹤0.01% 7287

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Jane Street's AKBA Position: Q1 2026 in Review

Jane Street increased its Akebia Therapeutics (AKBA) stake by 111% in Q1 2026, buying an estimated $1.05M and bringing the position to 1,456,674 shares worth $2.02M. The position accounts for ﹤0.01% of the portfolio, ranked #5074.

Jane Street first reported a position in AKBA in Q2 2014 and has held it in 33 quarters since. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Jane Street held 1,456,674 shares of Akebia Therapeutics worth $2.02M as of Q1 2026.
  • Jane Street bought 765,090 Akebia Therapeutics shares in Q1 2026, an estimated $1.05M.
  • Akebia Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #5074 holding.
  • Jane Street first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 33 quarters since.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.